Emmes

We’re counting down to #EBMT2025 in Florence! With over 35 years of expertise, Emmes is driving innovation in cell and gene therapy. Visit us at booth #40B to see how our tech-enabled, full-service solutions are enhancing clinical trial outcomes. Let’s discuss how we can help advance your cell and gene therapy research. Schedule a meeting now: https://lnkd.in/eGwYaf7h Victoria Coleman-Cowger, Denise King, Garrath Read #EBMT2025 #CellTherapy #GeneTherapy #Innovation #TechEnabledCRO #Emmes

We’re thrilled to be part of the The World Vaccine Congress 2025 in Washington! Join us at the forefront of vaccine innovation. As the industry’s leading vaccine specialized CRO, Emmes Group is revolutionizing vaccine and infectious disease research through agile, tech-enabled solutions. With our global footprint and local expertise, we deliver rapid execution and high-quality outcomes, designed to accelerate progress in vaccine trials. Visit us at Booth #501 to explore how our full-service, global offering is setting new standards for vaccine research and development. #VaccineInnovation #WorldVaccineCongress #GlobalCRO #AIInResearch #ClinicalTrials #VaccineResearch #VaxTrials #Emmes #EmmesGroup

Emmes is proud to highlight our work in advancing clinical neuroscience, from Phase I-IV trials to cutting-edge research in Alzheimer’s, MS, epilepsy, stroke, and rare diseases like Duchenne Muscular Dystrophy. Stop by Booth #708 and schedule a meeting to discuss how we can collaborate on your next neuroscience breakthrough. https://lnkd.in/ecpZVM_M #AAN2025 #Neuroscience #ClinicalResearch #Innovation #Neurology #HealthcareLeadership #EmmesResearch

We’re proud to be at #EBMT2025 in Florence, showcasing Emmes' 35+ years of expertise in advancing cell and gene therapies. Visit us at booth 40B to learn how our tech-driven, full-service solutions are accelerating progress in clinical trials, driving faster and more efficient outcomes. Meet our passionate team and let’s push the boundaries of cell therapy together! Schedule your meeting today: https://lnkd.in/eGwYaf7h #EBMT2025 #CellTherapy #GeneTherapy #TechEnabledCRO #Innovation #Emmes

The 2025 AAN Annual Meeting is where the brightest minds in neurology will be gathering to share groundbreaking discoveries and insights. At Emmes, we’re proud to be part of this event, showcasing our expertise in advancing clinical neuroscience. From Phase I-IV clinical trials to specialized research in Alzheimer’s, MS, epilepsy, stroke, and rare diseases like Duchenne Muscular Dystrophy, we’re helping shape the future of neurological treatments.   Join us in San Diego to connect, learn, and explore how Emmes can support your next big breakthrough in neuroscience research.   #AAN2025 #Neuroscience #ClinicalTrials #Neurology #NeuroResearch #NeuroInnovation #Emmes #ClinicalResearch    

Pediatric rare diseases present unique challenges that impact children and their families. Early intervention is critical, but pediatric trials require more than traditional methods. They must be patient-centered, considering both clinical outcomes and real-world experiences.   At Emmes, we combine industry expertise and personal experience to design tailored studies that meet the unique needs of pediatric patients. Our patient-focused approach helps expedite clinical development and improve outcomes.   Download the whitepaper now to discover how we can reshape pediatric rare disease trials together: https://lnkd.in/e7Fk42yi   #RareDisease #PediatricTrials #PatientCenteredResearch #ClinicalTrials #Emmes  

Join us at #EBMT25 in Florence! For over 35 years, Emmes has been at the forefront of cell therapy research, driving innovation from stem cell transplants to cutting-edge genomic therapies. At EBMT25, we’re excited to share insights into how our AI-powered, tech-driven CRO solutions are accelerating breakthroughs and improving patient outcomes.   Let’s connect and explore how Emmes is reaching new frontiers in cell and gene therapy! Schedule a meeting with us: https://lnkd.in/euUq2rfa #EBMT25 #Emmes #ClinicalTrials #HCT #CT #CRO

With 7,000 rare diseases affecting 350 million people worldwide, developing effective treatments comes with significant challenges. One of the most complex aspects is patient recruitment and retention, particularly when working with small, geographically dispersed populations and the additional considerations of enrolling pediatric patients. Overcoming these barriers requires a strategic approach—from well-designed trial protocols and experienced sites to data-driven recruitment strategies and strong collaboration with advocacy groups and caregivers. Our latest whitepaper, Enhancing Recruitment and Retention in Rare Disease Trials, explores the key factors that contribute to successful trial participation and long-term engagement. Download the whitepaper to learn more: https://hubs.la/Q03bm3Vk0 #RareDisease #ClinicalTrials #PatientEngagement

We’re excited to collaborate with Developing Countries Vaccine Manufacturers Network (DCVMN International) for the VaxTRIALS, part of Emmes Group, Webinar: “Participant-Centered Approach: Key Factor for Successful Enrollment & High Retention in Vaccine Studies” Join us on 6th March from 14:00 – 15:30 to discover how a participant-centered approach boosts enrollment, visit compliance, and retention in vaccine studies. Learn from real-world evidence and explore the VaxTRIALS Recruitment & Adherence Model to enhance participant engagement and study success. Our expert speakers: Dr. Jose Jimeno, Senior Vice President, Vaccines & Infectious Diseases Unit Erika Rodriguez Parra, Clinical Recruitment & Adherence Manager Dr. Eduardo Lopez-Medina, Scientific Director Laura Rivera, Vice President-Executive Director Register today and secure your spot: https://lnkd.in/eee6ej3Y #VaccineStudies #ClinicalTrials #ParticipantCentric #Webinar #Healthcare #DCVMN

In rare disease research, every patient counts. A truly patient-first approach can be the difference between a successful trial and one that struggles due to recruitment and retention challenges. With smaller patient populations, rare disease trials face unique hurdles—from slow recruitment and under-enrollment to difficulty retaining participants. Having the right strategies in place is critical to keeping your trial on track. Our infographic, “Path to a Successful Rare Disease Trial,” breaks down the key recruitment and retention strategies you need to succeed. Check it out! 👇 Visit the link to learn more: https://hubs.la/Q038-RGT0 #RareDisease #ClinicalTrials #PatientCentric